Antenatal Corticosteroids: Short-Term Gains, Long-Term Questions-A Meta-Analysis

Marharyta Sobczak1, Barbara Wencka2, Rafał Pawliczak1

  • 1Department of Immunopathology, Division of Biomedical Science, Faculty of Medicine, Medical University of Lodz, 90-752 Lodz, Poland.

Insights

Antenatal corticosteroids (ACSs) reduce newborn mortality but may increase risks for neurodevelopmental disorders. This meta-analysis found increased risks for neurocognitive, hearing, autism, and mental/behavioral disorders following prenatal ACS exposure.

Area of Science:

  • Obstetrics and Gynecology
  • Neonatal Medicine
  • Developmental Pediatrics

Background:

  • Antenatal corticosteroids (ACSs) are crucial for preterm birth management, reducing neonatal mortality and morbidity.
  • Concerns exist regarding potential long-term adverse effects of fetal exposure to ACSs.
  • This meta-analysis evaluates the association between prenatal corticosteroid exposure and long-term health outcomes.

Purpose of the Study:

  • To synthesize evidence on the long-term neurological and other outcomes following prenatal exposure to corticosteroids.
  • To quantify the risk of specific developmental disorders associated with ACS exposure.

Main Methods:

  • Comprehensive literature search of PubMed, Web of Science, and Cochrane Register up to January 2026.
  • Inclusion of randomized controlled trials and observational studies reporting long-term outcomes.
  • Meta-analysis using a random effects model to calculate pooled effect sizes.

Main Results:

  • Increased risk observed for suspected neurocognitive disorder (RR=1.17), hearing impairment (RR=1.18), autism spectrum disorders (RR=1.25), and any mental/behavioral disorder (RR=1.25).
  • A slight increase in visual impairment risk was noted (RR=1.03).
  • No statistically significant associations were found for other neurological disorders or outcomes.

Conclusions:

  • Prenatal corticosteroid exposure may be linked to an elevated risk of specific long-term neurological issues.
  • Findings necessitate cautious interpretation due to established neonatal benefits.
  • Further long-term observational studies are required to fully assess the benefit-risk profile of ACSs.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...